Compounds having the following formula ##STR1##wherein L, M, R.sup.2, R.sup.3, R.sup.4, R.sup.5, R.sup.6, R.sup.7, X.sup.1 and X.sup.2 are as defined in the specification, pharmaceutically-acceptable salt thereof, useful for treating depression, anxiety, asthma, rheumatoid arthritis, Alzheimer's disease, cancer, schizophrenia, oedema, allergic rhinitis, inflammation, pain, gastrointestinal-hypermotility, emesis, Huntington's disease, psychoses, hypertension, migraine, bladder hypermotility, or urticaria, compositions including such compounds and processes for making such compounds.

Astrazeneca AB

Naphthalenecarboxamides as tachykinin receptor antagonists

This invention relates to benzimidazolone derivatives, represented by compounds of a general formula [I] ##STR00001## [in which R.sup.1 and R.sup.2 stand for, e.g., hydrogen atoms; R.sup.3a, R.sup.3b, R.sup.4, R.sup.5 stand for, e.g., hydrogen atoms and alkyl groups; R.sup.6 stands for e.g., aryl or heteroaryl groups; A ring stands for 5- to 8-membered aliphatic heterocyclic ring containing one nitrogen atom; and Z stands for carbonyl group or sulfonyl group]. The benzimidazolone derivatives of the invention exhibit antagonism to muscarinic acetylcholine receptors, and are useful as treating agent and/or prophylactic of Parkinson's disease, drug-induced parkinsonism, dystonia, akinesia, pancreatitis, bilestone/cholecystitis, biliary dyskinesia, achalasia, pain, itch, cholinergic urticaria, irritable bowel syndrome, vomiting, nausea, dizziness, Meniere's disease, motion sickness and urinary disturbance.

urticaria/opkast

Naphthalenecarboxamides as tachykinin receptor antagonists

Benzimidazolone derivatives

Den mest komplette database med medicinske urter understøttet af videnskab